Listen on the go
Downloads

View and download resources from this activity to support your learning and share with colleagues

Download Slides
Download Practice Aid
Download Slides
Download Slides
Download Slides
Download Slides
Download Slides
CORRECT!
Next question
Faculty & Disclosures
Dr Lizza Hendriks

Maastricht University Medical Center, Maastricht, The Netherlands

Dr Lizza Hendriks is a pulmonologist specializing in lung cancer at Maastricht University Medical Center, The Netherlands, where she leads the Clinical Lung Cancer Research Department. Her main interest is in brain metastases in patients with lung cancer, obtaining a PhD on this topic in 2016. read more

Dr Hendriks leads the Innovative Cancer Diagnostics Therapy group at the School for Oncology and Developmental Biology (GROW) at Maastricht University and is (local) principal investigator in several phase II and III clinical trials, focusing on (locally) advanced NSCLC and SCLC, targeted treatments and immunotherapies. She is an active member of Dutch (Dutch Society of Pulmonology [NVALT] and the Tuberculosis and Netherlands Respiratory Society), European (European Organisation for Research and Treatment of Cancer [EORTC], European Respiratory Society, European Society for Medical Oncology [ESMO] and the European Thoracic Oncology Platform) and global societies (American Society of Clinical Oncology and the International Association for the Study of Lung Cancer). Dr Hendriks is secretary of the NVALT studies foundation and chairs the EORTC sub-committee on Systemic Treatment for Metastatic NSCLC. She is a member of national and ESMO guideline committees and is a programme committee member or chair of several international conferences. She is a member of the Young Academy of the Royal Netherlands Academy of Arts and Sciences.

Dr Lizza Hendriks discloses: Advisory board or panel fees from Amgen, Anheart, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Lilly, Merck, MSD, Novartis, Pfizer and Takeda. Grants/research support from AbbVie, Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim (relationship terminated), Gilead, GSK, Merck, Mirati, MSD, Novartis, Pfizer, Roche Genentech and Takeda. Other financial or material support (royalties, patent, etc.) from Secretary NVALT studies foundation and Subchair EORTC metastatic NSCLC systemic therapy. Speaker’s bureau fees from AstraZeneca, Bayer, Benecke, GSK, High5 Oncology, Janssen, Lilly, MSD, Pfizer, Sanofi and Takeda.
Dr Jacob Sands

Dana-Farber Cancer Institute, Boston, MA, USA

Dr Jacob Sands is a thoracic oncologist at the Dana-Farber Cancer Institute, Boston, MA, USA, who specializes in treating lung cancer and conducts clinical and translational work in lung cancer diagnostics and treatment. read more

Dr Sands leads a National Cancer Institute-sponsored adjuvant non-small cell lung cancer (NSCLC) study with planned enrolment of >1,200 patients, is a co-author of manuscripts that have changed the SCLC paradigm, including lurbinectedin and tarlatamab, as well as a lead author and presenter of datopotamab deruxtecan for NSCLC. He is also a co-founder and president of the Rescue Lung Society, a non-profit medical society focused on advancing lung screening.

Dr Jacob Sands discloses: Consultancy fees from AbbVie, Amgen, AstraZeneca, Daiichi Sankyo, G1 Therapeutics, Guardant, Lilly, Medtronic, Merck, Pharma Mar and Sanofi (all relationships terminated).
Prof. Suresh Senan

Amsterdam University Medical Center, Amsterdam, The Netherlands

Professor Suresh Senan is a radiation oncologist at the Amsterdam University Medical Center in The Netherlands. read more

His research has focused on trials of systemic agents and radiation for lung malignancies, new radiotherapy techniques and studying population outcomes. He is a faculty member for thoracic malignancies at the European Society of Medical Oncology and the International Association for the Study of Lung Cancer.

Prof. Suresh Senan discloses: Advisory board or panel fees from AstraZeneca, BMS, MSD and Varian Medical Systems. Grants/research support from AstraZeneca.
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Immunotherapy

    International Partner

    An Introduction to Immunotherapy

    Cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Monoclonal antibodies and immune checkpoint inhibitors are now an established part of the treatment paradigm for many types of cancer, but challenges remain around its efficacy, targeting and toxicity.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Immunotherapy Content

    Lung Cancer, Immunotherapy
    Watch Time: 39 mins
    touchMDT
    Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors
    CE/CME ACCREDITED Dr Lizza Hendriks, Dr Jacob Sands, Prof. Suresh Senan Translations available:

    A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).

    Learning objectives
    Learning Objectives
    • Evaluate the potential role of immune checkpoint inhibitors in the treatment of patients with limited-stage small cell lung cancer
    • Recall the latest data for ICIs in LS-SCLC
    • Examine the possible impact of ICIs on the management of patients with LS-SCLC
    Head and Neck Cancer, Immunotherapy
    Watch Time: 15 mins
    touchFOCUS
    Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors
    CE/CME ACCREDITED Prof. Barbara Burtness

    Watch Prof. Barbara Burtness provide an update on the evolving role of ICIs in the management of RM-NPC.

    Learning objectives
    Learning Objectives
    • Discuss the role of immune checkpoint inhibitors in the first-line setting for recurrent or metastatic nasopharyngeal carcinoma
    • Summarize the use of immune checkpoint inhibitors in the second- and subsequent-line treatment of recurrent or metastatic nasopharyngeal carcinoma
    Breast Cancer, Dermatological Cancers, Gastrointestinal Cancers, Genitourinary Cancer, Gynaecological Cancers, Haematological Malignancies, Haematology, Head and Neck Cancer, Immunotherapy, Lung Cancer, Endocrine Cancers, Paediatric Oncology
    Space medicine: Can microgravity transform pharmaceutical manufacturing?

    In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

    Renal Cancer, Genitourinary Cancer, Immunotherapy
    Watch Time: 18 mins
    touchFOCUS
    Personalizing care within the MDT for patients with early through to advanced RCC
    CE/CME ACCREDITED Prof. Hans Hammers

    Watch an expert in RCC discuss multidisciplinary team care for patients with early through advanced disease.

    Learning objectives
    Learning Objectives
    • Apply diagnostic and prognostic markers and clinical data within the MDT to personalize care for patients with early stage through advanced and metastatic renal cell carcinoma
    • Use effective communication strategies and encourage shared decision-making when managing diverse and/or underserved patients with renal cell carcinoma
    Lung Cancer, Immunotherapy
    Watch Time: 33 mins
    touchEXPERT OPINIONS
    Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines
    CE/CME ACCREDITED Prof. Heather A Wakelee Translations available:

    Prof. Wakelee discusses the latest evidence on immunotherapy for early-stage, resectable NSCLC.

    Learning objectives
    Learning Objectives
    • Recall the recent advances in immunotherapy for early-stage NSCLC in the neoadjuvant/adjuvant settings
    • Describe how immunotherapy fits in the treatment algorithm for early-stage NSCLC
    • Summarize the key eligibility criteria for neoadjuvant/adjuvant immunotherapy, including clinical characteristics and biomarkers
    Bladder Cancer, Genitourinary Cancer, Immunotherapy
    Watch Time: 32 mins
    touchEXPERT OPINIONS
    Advanced urothelial carcinoma: Expert guidance to navigate an evolving therapeutic landscape
    CE/CME ACCREDITED Prof. Thomas Powles Translations available:

    Prof. Powles considers the latest developments in the treatment of advanced urothelial carcinoma.

    Learning objectives
    Learning Objectives
    • Choose appropriate treatments for patients with advanced urothelial carcinoma who are ineligible for or whose disease does not respond to first-line platinum-based chemotherapy
    • Outline how new and emerging therapies can be integrated in the treatment algorithm for advanced urothelial carcinoma
    • Manage adverse events of newly approved agents and combination therapies
    Gynaecological Cancers, Immunotherapy
    Watch Time: 38 mins
    touchEXPERT OPINIONS
    Clinical decision making with immunotherapies in advanced or recurrent endometrial cancer
    CE/CME ACCREDITED Prof. David Cibula

    Hear expert insights on the role of immunotherapy in treating advanced/recurrent endometrial cancer.

    Learning objectives
    Learning Objectives
    • Describe the role of molecular classification in optimal treatment selection for patients with advanced or recurrent endometrial cancer
    • Evaluate the established role of immunotherapies for treating advanced or recurrent endometrial cancer according to guideline recommendations
    • Discuss the impact of utilizing immunotherapy combination strategies for advanced or recurrent endometrial cancer in earlier lines of treatment
    Head and Neck Cancer, Immunotherapy
    Watch Time: 32 mins
    touchEXPERT OPINIONS
    What’s on the horizon to tackle unmet needs in recurrent/metastatic SCCHN?
    CE/CME ACCREDITED Dr Aline Chaves, Prof. Makoto Tahara, Dr Ranee Mehra Translations available:

    Experts consider current unmet needs and possible future treatment directions for R/M SCCHN.

    Learning objectives
    Learning Objectives
    • Recall unmet treatment needs for patients with recurrent/metastatic SCCHN
    • Discuss the rationale and latest data for immunotherapy-based treatments in development for recurrent/metastatic SCCHN
    • Evaluate the rationale and latest data for investigational targeted therapies for recurrent/metastatic SCCHN
    Lung Cancer, Immunotherapy
    Watch Time: 18 mins
    touchFOCUS
    Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy
    CE/CME ACCREDITED Dr Balazs Halmos

    Dr Balazs Halmos offers his perspective on immunotherapy for the treatment of squamous cell lung cancer.

    Learning objectives
    Learning Objectives
    • Summarize the key clinical features of advanced squamous cell lung cancer and the challenges they pose to its management
    • Interpret the most recent clinical data to guide systemic therapy selection for squamous cell lung cancer
    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup